Yayın:
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorScott J. Rodig
dc.contributor.authorВ Я Мельниченко
dc.contributor.authorCatherine Thiéblemont
dc.contributor.authorKamal Bouabdallah
dc.contributor.authorGayane Tumyan
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorSergio Portiño
dc.contributor.authorLaura Maria Fogliatto
dc.contributor.authorMarı́a Dolores Caballero
dc.contributor.authorJan Walewski
dc.contributor.authorZafer Gülbaş
dc.contributor.authorVincent Ribrag
dc.contributor.authorBeth Christian
dc.contributor.authorGuilherme Fleury Perini
dc.contributor.authorGilles Salles
dc.contributor.authorJakub Svoboda
dc.contributor.authorJasmine Zain
dc.contributor.authorSanjay S. Patel
dc.contributor.authorPei-Hsuan Chen
dc.contributor.authorAzra H. Ligon
dc.contributor.authorJing Ouyang
dc.contributor.authorDonna Neuberg
dc.contributor.authorRobert Redd
dc.contributor.authorArkendu Chatterjee
dc.contributor.authorArun Balakumaran
dc.contributor.authorRobert Orlowski
dc.contributor.authorMargaret A. Shipp
dc.contributor.authorPier Luigi Zinzani
dc.contributor.orcid0000-0001-6098-1603
dc.contributor.orcid0000-0003-1761-9769
dc.contributor.orcid0000-0002-6728-6264
dc.contributor.orcid0000-0002-9941-2448
dc.contributor.orcid0000-0002-5771-4413
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0002-2996-620X
dc.contributor.orcid0000-0002-0610-7971
dc.contributor.orcid0000-0003-4247-2674
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0002-5221-353X
dc.contributor.orcid0000-0001-7235-1334
dc.contributor.orcid0000-0002-9541-8666
dc.contributor.orcid0000-0002-6359-7065
dc.contributor.orcid0009-0009-0753-1019
dc.contributor.orcid0000-0001-7621-453X
dc.contributor.orcid0000-0001-7585-2441
dc.contributor.orcid0000-0001-5902-7070
dc.contributor.orcid0000-0003-2566-3145
dc.contributor.orcid0000-0002-1329-5288
dc.contributor.orcid0000-0001-7884-6928
dc.contributor.orcid0000-0002-8037-9932
dc.contributor.orcid0000-0002-3949-6897
dc.contributor.orcid0000-0002-2112-2651
dc.date.accessioned2025-11-12T22:29:22Z
dc.date.issued2019-10-14
dc.identifier.doi10.1200/jco.19.01389
dc.identifier.endpage3299
dc.identifier.issn0732-183X
dc.identifier.issue34
dc.identifier.openalexW2979952645
dc.identifier.startpage3291
dc.identifier.urihttps://hdl.handle.net/11421/120
dc.identifier.urihttps://doi.org/10.1200/jco.19.01389
dc.identifier.volume37
dc.language.isoen
dc.relation.ispartofJournal of Clinical Oncology
dc.rightsopenAccess
dc.subjectMedicine
dc.subjectPembrolizumab
dc.subjectRefractory (planetary science)
dc.subjectLymphoma
dc.subjectOncology
dc.subjectInternal medicine
dc.subjectCancer research
dc.subjectCancer
dc.subjectImmunotherapy
dc.subject.sdg3
dc.titlePembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications